(Q37235973)

19 August 2017

Effect of ingested interferon-alpha on beta-cell function in children with new-onset type 1 diabetes (English)

1 reference

19 August 2017

0 references

0 references

Kristina I Rother

1

1 reference

19 August 2017

Rebecca J Brown

2

1 reference

19 August 2017

Miriam M Morales

3

1 reference

19 August 2017

Elizabeth Wright

4

1 reference

19 August 2017

Zhigang Duan

5

1 reference

19 August 2017

Carol Campbell

6

1 reference

19 August 2017

Dana S Hardin

7

1 reference

19 August 2017

Jadranka Popovic

8

1 reference

19 August 2017

Robert C McEvoy

9

1 reference

19 August 2017

David M Harlan

10

1 reference

19 August 2017

Philip R Orlander

11

1 reference

19 August 2017

Staley A Brod

12

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 July 2009

1 reference

19 August 2017

1 reference

19 August 2017

32

1 reference

19 August 2017

1250-1255

1 reference

19 August 2017

7

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

19 August 2017

start time

28 August 2021

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

GAD treatment and insulin secretion in recent-onset type 1 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Type 1 diabetes intervention trials 2007: where are we and where are we going?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Hormetic dose-response relationships in immunology: occurrence, quantitative features of the dose response, mechanistic foundations, and clinical implications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Ingested interferon alpha suppresses type I diabetes in non-obese diabetic mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Combination of nicotinamide and steroid versus nicotinamide in recent-onset IDDM. The IMDIAB II Study.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Double-blind controlled trial of azathioprine in children with newly diagnosed type I diabetes.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Type 1 diabetes mellitus provoked by peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Ingested IFN-alpha: results of a pilot study in relapsing-remitting MS.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Interaction of bromocriptine and cyclosporine in insulin dependent diabetes mellitus: results from the Canadian open study.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2699745

Ingested IFN-alpha preserves residual beta cell function in type 1 diabetes

3 September 2018

1 reference

12 December 2020

Remissions in newly diagnosed type 1 (insulin-dependent) diabetes: influence of interferon as an adjunct to insulin therapy

1 reference

12 December 2020

Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus

1 reference

12 December 2020

Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group

1 reference

12 December 2020

Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin

1 reference

12 December 2020

Double-blind randomized trial of nicotinamide on early-onset diabetes

1 reference

12 December 2020

Absence of Biological Effects of Orally Administered Interferon-βser

1 reference

12 December 2020

Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppression of chronic relapsing experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Identifiers

DOI

10.2337/DC08-2029

1 reference

19 August 2017

1 reference

19 August 2017

1 reference